Please login to the form below

Not currently logged in
Email:
Password:

Microsoft signs agreement with Merck & Co

Microsoft is to acquire certain assets of Rosetta Biosoftware, a business unit of Rosetta Inpharmatics – a wholly owned subsidiary of Merck & Co

Microsoft is to acquire certain assets of Rosetta Biosoftware, a business unit of Rosetta Inpharmatics – a wholly owned subsidiary of Merck & Co.

The deal will enable Microsoft to enhance its Amalga Life Sciences platform through the incorporation of genetic, genomic, metabolomic and proteomics data management software.

Under the terms of the agreement, Merck will become a customer of the Microsoft Amalga Life Sciences 2009 platform and will provide strategic input to Microsoft.

The acquisition forms part of Merck's strategy to ensure long-term pipeline productivity through improved effectiveness and efficiency of basic research operations.

"This agreement establishes a stable and sustainable platform for the Rosetta Biosoftware technology. In addition, we look forward to collaborating with Microsoft to develop new bioinformatic solutions to enable and expedite drug discovery and development," said Rupert Vessey, vice president, Merck Research Laboratories.

The Amalga Life Sciences platform automates the analysis of massive, heterogeneous research data and provides scientists and researchers across all life sciences with the opportunity to manage, redesign and control research processes.

The deal is due to close at the end of June 2009. Microsoft is looking into hiring key Rosetta Biosoftware staff to fill roles critical to the effective amalgamation of the technology.

3rd June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics